IL6R and breast carcinoma: The functional importance of IL6-STAT3 activation in PTEN-deleted HER2-positive breast cancer was demonstrated in a study showing that the IL6R antibody, alone or in combination with trastuzumab, decreased the cancer stem cell population and inhibited development of distant metastasis [21].